Bevacizumab (Avastin) for Choroidal Neovascularization
|60,737 Patients Studied||563 Studies (View)|
Definition: Bevacizumab is a drug that blocks angiogenesis, the growth of new blood vessels. It is used to treat various cancers, including colorectal, lung, and kidney cancer, and eye disease. Bevacizumab is a humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A). VEGF-A is a chemical signal that stimulates angiogenesis in a variety of diseases, especially in cancer, retinal proliferation of diabetes in the eye. Choroidal neovascularization (CNV) is the creation of new blood vessels in the choroid layer of the eye. This is a common symptom of the degenerative maculopathy wet AMD. (SOURCE: Wikipedia)
Where does Bevacizumab (Avastin) rank compared to other Choroidal Neovascularization treatments?
Health experts published 563 studies on Bevacizumab and Choroidal Neovascularization making Bevacizumab the #1 most researched treatment. In research involving Choroidal Neovascularization, experts have concluded that Bevacizumab is effective in 61 studies and safe in 50 studies.
Health experts published 402 studies on Verteporfin and Choroidal Neovascularization making Verteporfin the #2 most researched treatment. In research involving Choroidal Neovascularization, experts have concluded that Verteporfin is effective in 30 studies and safe in 54 studies.
Health experts published 320 studies on Intravitreal Injection and Choroidal Neovascularization making Intravitreal Injection the #4 most researched treatment.
What does the FDA say about side effects?
Most Researched Conditions
What other conditions have been studied?
What treatments have patients discontinued using?
What treatments are patients switching to?